JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · 2017 · 37 citations · 27 references
MedicineOncologyPathologyMetastasisNeoplasiaTumor PathologyImmunohistochemistryMalignant NeoplasmsMalignant TumorsOvarian CancerTumor GradingTumor MarkersCellular ProliferationGrowth FractionHistological TypingKi-67 ImmunostainingKi-67 Labeling IndexOvarian Cancer Prognostic BiomarkersOvarian Surface Epithelial TumorsSerous Ovarian Tumors
INTRODUCTION: The Surface Epithelial Ovarian Carcinoma (SEOC) at the moment of diagnosis, the disease is extended beyond the structures of the pelvis. Ki-67 is one of the prognostic marker which determines the growth fraction of a tumour and its over expression is associated with malignancy, tumour aggression, reserved prognosis and metastasis. AIM: To evaluate the proliferative activity using Ki-67 immuno-staining in SEOC and to correlate with histological subtype, grade, Federation of Gynecology and Obstetrics (FIGO) stage, CA125 levels for diagnostic and prognostic purpose. MATERIALS AND METHODS: The study was conducted in JSS Medical College and Hospital, JSS University, Mysuru. It was a descriptive cross-sectional study involving 40 cases of SEOC over a period of two years. The proliferation expression related to Ki-67 antigen was evaluated by immunohistochemical monoclonal MIB-1 antibody. In each case, the Ki-67 labeling index (Ki-67 LI) was articulated as percentage of positively stained cells using high power objective of the microscope (x400). RESULTS: Among the 40 carcinomas, 26 were serous, five mucinous, four each of clear cell and undifferentiated and one transitional cell carcinoma. A total of 75% were high grade tumours. High Ki-67 LI was associated with high grade tumours (69.9%), high grade serous tumours (65.34%) and advanced FIGO staging (70.6%) with the p-value of <0.001. CA 125 levels did not have a significant correlation with Ki-67 LI. CONCLUSION: Ki-67 is an exceptionally a cost effective marker to determine the growth fraction of a tumour cell population. In SEOC histological grade and FIGO stage when combined with Ki-67 LI in histopathology report would help in diagnostic differentiation of subtypes, prognostication, deciding the need for adjuvant chemotherapy and in predicting survival analysis.
27
Ahmedin Jemal, Rebecca L. Siegel, Elizabeth Ward et al. · CA A Cancer Journal for Clinicians · 2007 · 7.5K citations · Full text
Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Martin Köbel, Steve E. Kalloger, Niki Boyd et al. · PLoS Medicine · 2008 · 820 citations · Full text
New insights into ovarian cancer pathology
Jaime Prat · Annals of Oncology · 2012 · 317 citations · Full text